机构：[1]Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China[2]Institute of Radiotherapy and Oncology, Soochow University, Suzhou, Jiangsu 215004, P.R. China[3]Department of Pharmacy, The Affiliated Children's Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China[4]Center of Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
Androgens have been recognized to be primary causative agents of prostate cancer. Following binding to the androgen receptor (AR), androgens serve important roles in the carcinogenesis of prostate cancers. ARs serve an important role during all stages of prostate cancer, and inhibiting their function may help to slow prostate cancer growth. In the present study, the AR gene was targeted in androgen-positive prostate cancer cells using the clustered regularly interspaced short palindromic repeats-associated protein (CRISPR/Cas) system. A total of three different single-guide RNAs (sgRNAs) were designed according to the three different target sites in the AR gene. The optimal sgRNA with a specific target effect was effectively screened to cleave the AR gene in androgen-positive prostate cancer cell lines, and to suppress the growth of androgen-sensitive prostate cancer in vitro. The AR-sgRNA-guided CRISPR/Cas system was able to disrupt the AR at specific sites and inhibit the growth of androgen-sensitive prostate cancer cells; further studies demonstrated that the decreased cell proliferation was due to cellular apoptosis. The results of the present study suggested that the CRISPR/Cas system may be a useful therapeutic strategy for the treatment of prostate cancer.
基金：
The authors were financially supported by the Suzhou Science and Technology Bureau Development Plan (grant no. SYS201475), the Jiangsu Provincial Special Program of Clinical Medical Science (grant no. BL2014040), the Suzhou Clinical Special Disease Diagnosis and Treatment Program (grant no. LCZX201406), the Suzhou Science and Technology Development Plan (grant no. SS201534), and the Suzhou Science and Technology Development Plan Guidance Project (grant no. SYSD2015091). This project additionally received the Second Affiliated Hospital of Soochow University Preponderant Clinic Discipline Group project funding (grant no. XKQ2015009).
第一作者机构：[1]Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China[2]Institute of Radiotherapy and Oncology, Soochow University, Suzhou, Jiangsu 215004, P.R. China
共同第一作者：
通讯作者：
通讯机构：[*1]Center of Laboratory, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, Jiangsu 215004, P.R. China[*2]Department of Radiology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, Jiangsu 215004, P.R. China
推荐引用方式(GB/T 7714)：
CHAOGANG WEI,FENGJIAO WANG,WEI LIU,et al.CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells[J].MOLECULAR MEDICINE REPORTS.2018,17(2):2901-2906.doi:10.3892/mmr.2017.8257.
APA：
CHAOGANG WEI,FENGJIAO WANG,WEI LIU,WENLU ZHAO,YI YANG...&JUNKANG SHEN.(2018).CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells.MOLECULAR MEDICINE REPORTS,17,(2)
MLA：
CHAOGANG WEI,et al."CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells".MOLECULAR MEDICINE REPORTS 17..2(2018):2901-2906
